However, there are a number of limitations with these biomarkers in the context of HF management; the biological variation of BNP or N‐terminal proBNP is ~30% in chronic HF, and levels are further influenced by patient weight, comorbidities, and medications.2 The gene discussed is NPPB; the disease is hydrops fetalis.